
    <html>
    <head>
      <meta charset="utf-8">
      <style>
        @page {
          size: A5;
          margin: 2cm;
        }
        body {
          font-family: -apple-system, BlinkMacSystemFont, "SF Pro Text", Helvetica, Arial, sans-serif;
          font-size: 15pt;
          line-height: 1.5;
          color: #111;
          word-wrap: break-word;
          overflow-wrap: anywhere;
          margin: 20px;
        }
        h1 { font-size: 22pt; margin-bottom: 0.6em; }
        h2 { font-size: 18pt; margin-top: 1.2em; }
        h3 { font-size: 15pt; }
        a { color: #0a58ca; text-decoration: underline; pointer-events: auto; }
        table {
          width: 100%;
          border-collapse: collapse;
          table-layout: fixed;
          font-size: 12.5pt;
        }
        th, td {
          border: 1px solid #ccc;
          padding: 6px;
          word-wrap: break-word;
          overflow-wrap: anywhere;
          vertical-align: top;
        }
        tr:nth-child(even) { background-color: #f9f9f9; }
        pre, code {
          font-family: Menlo, Monaco, monospace;
          font-size: 11.5pt;
          white-space: pre-wrap;
          word-wrap: break-word;
        }
      </style>
    </head>
    <body>
      <p>Below is a concise, fact-checked research brief on Nano-X Imaging Ltd. (Nasdaq: NNOX) as of December 22, 2025.</p>
<p>1) Company Overview
- What it does
  - Med‑tech company developing and commercializing the Nanox.ARC/X multi‑source 3D digital tomosynthesis X‑ray systems, plus an integrated platform: Nanox.AI (FDA‑cleared CT analytics), Nanox.CLOUD (workflow/storage), and USARAD teleradiology services. (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanoxarc-imaging-system-receives-fda-clearance-pioneering-new?utm_source=openai">investors.nanox.vision</a>)
- Business model and revenue streams
  - Hardware: sale/deployment of Nanox.ARC/ARC X systems (with potential for service/bundled models).
  - Software/AI: per‑study/per‑site licenses for AI (HealthCCSng cardiac, HealthOST bone, HealthFLD liver).
  - Services: teleradiology/marketplace via USARAD. (<a href="https://www.globenewswire.com/news-release/2025/11/18/3189949/0/en/Nanox-Announces-Strategic-Partnership-with-3DR-Labs-to-Expand-AI-Powered-Imaging-Solutions-Across-North-America.html?utm_source=openai">globenewswire.com</a>)
- Key regulatory status
  - FDA 510(k) for multi‑source Nanox.ARC general use expanded in Dec 2024 (musculoskeletal, pulmonary, intra‑abdominal, paranasal) and additional clearance for ARC X in Apr 2025. CE Mark for ARC in the EU in Feb 2025. (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanoxarc-imaging-system-receives-fda-clearance-general-use?utm_source=openai">investors.nanox.vision</a>)
- Competitive positioning
  - Early‑stage challenger in imaging hardware and AI versus entrenched OEMs (GE HealthCare, Siemens Healthineers, Philips) and service providers (e.g., RadNet in services). Differentiation centers on solid‑state digital X‑ray source enabling a compact, lower‑infrastructure 3D tomosynthesis system and a full “scan‑to‑diagnosis” stack. (<a href="https://nano-ximaging.gcs-web.com/news-releases/news-release-details/nanox-opens-south-korean-fabrication-plant-produce-semiconductor?utm_source=openai">nano-ximaging.gcs-web.com</a>)</p>
<p>2) Recent Financial Performance (latest reported)
- Stock snapshot (Dec 20, 2025 intraday)
  - Price: $2.99. Market cap estimate: ~$207M (StockAnalysis). (<a href="https://stockanalysis.com/stocks/nnox/market-cap/?utm_source=openai">stockanalysis.com</a>)
- Quarterly results (US$)
  - Q3 2025 (reported Nov 20, 2025): Revenue $3.4M (+13% YoY; +13% QoQ), GAAP gross loss $(2.9)M, net loss $(13.7)M. Mix: teleradiology $3.1M, imaging/OEM $0.175M, AI $0.142M. Cash &amp; marketable securities $55.5M (Sep 30). 2026 revenue guidance: $35M. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
  - Q2 2025: Revenue $3.04M, net loss $(14.7)M; cash $62.6M (Jun 30). (<a href="https://www.google.com/finance/quote/NNOX%3ANASDAQ?utm_source=openai">google.com</a>)
  - Q1 2025: Revenue $2.8M, net loss $(13.2)M; cash &amp; investments $72.9M (Mar 31). (<a href="https://www.beyondspx.com/quote/NNOX/news/nanox-announces-first-quarter-2025-financial-results-with-increased-net-loss?utm_source=openai">beyondspx.com</a>)
- Liquidity, cash burn, capital raises
  - Operating cash flow (nine months ended Sep 30, 2025): $(30.4)M. Registered direct offering closed Nov 25, 2025 raised ~$15M (3.83M new shares). (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>) (<a href="https://www.sec.gov/Archives/edgar/data/0001795251/000121390025114902/ea0267192-6k_nanox.htm">sec.gov</a>)
  - Total liabilities were ~$20.7M as of Jun 30, 2025 (low leverage). (<a href="https://www.google.com/finance/quote/NNOX%3ANASDAQ?utm_source=openai">google.com</a>)
- Simple table (US$)
  - Revenue: Q3’25 $3.4M | Q2’25 $3.0M | Q3’24 $3.0M. Net loss: Q3’25 $(13.7)M | Q2’25 $(14.7)M. Cash &amp; investments: Sep 30, 2025 $55.5M; Jun 30, 2025 $62.6M. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Valuation metrics (reference)
  - P/B ~1.6 (Google Finance, Jun‑Q data); EV ≈ $170M; EV/Sales TTM ≈ 12.8x; EV/EBITDA negative (≈ −3.7x; not meaningful). Peers: GEHC EV/EBITDA ~11x–12x; Siemens Healthineers ~10x–14x; Philips EV/Sales ~1.6x; RadNet EV/EBITDA ~21x. (<a href="https://www.google.com/finance/quote/NNOX%3ANASDAQ?utm_source=openai">google.com</a>)</p>
<p>3) Business Quality and Moat
- Competitive advantages
  - Novel digital “cold cathode” multi‑source X‑ray enabling 3D tomosynthesis with compact footprint and “plug‑and‑play” install (ARC X); regulatory clearances in US/EU; growing clinical data; full‑stack platform (hardware+AI+telerad). (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanox-receives-fda-clearance-general-use-new-imaging-system/?utm_source=openai">investors.nanox.vision</a>)
- Key differentiators
  - Potentially lower infrastructure vs CT, adjunct to radiography, integrated AI and teleradiology for end‑to‑end workflows. Manufacturing partnership with Varex for tubes using Nanox’s digital source. (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanoxarc-imaging-system-receives-fda-clearance-general-use?utm_source=openai">investors.nanox.vision</a>)
- Risks to moat
  - Scale and distribution versus incumbents; negative gross margins for imaging and AI segments; commercialization execution still early. Q3’25 showed imaging/AI gross losses; only teleradiology carried GAAP gross profit (~25%). (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Concentration/exposure
  - Revenue still concentrated in teleradiology; hardware/AI ramp ongoing. Supply/manufacturing reliance on partners and internal source‑chip fabrication. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Pricing power and margins
  - Evidence of improving teleradiology margins (GAAP 25% in Q3’25), but imaging/AI remain loss‑making at current scale; margin durability hinges on installed base growth and AI deployments. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)</p>
<p>4) Management and Leadership Assessment
- Team
  - CEO: Erez Meltzer (ex‑Hadassah Medical Center Chair; led multiple global firms; Acting Chairman since 2024). CFO: Ran Daniel (25+ years finance). (<a href="https://investors.nanox.vision/management-team?utm_source=openai">investors.nanox.vision</a>)
- Capital allocation and track record
  - Secured US/EU regulatory milestones (2023–2025), raised capital via ATM (2024) and a registered direct (Nov 2025), acquiring VasoHealthcare IT to speed AI deployments. (<a href="https://nano-ximaging.gcs-web.com/news-releases/news-release-details/nanox-announces-fourth-quarter-2024-financial-results-and?utm_source=openai">nano-ximaging.gcs-web.com</a>)
- Insider activity/governance
  - CFO bought 1,000 shares on Sep 5, 2025. Company and former CEO settled SEC charges in 2023 regarding earlier manufacturing‑cost disclosures; separate securities class action proposed settlement announced Dec 2023. (<a href="https://www.investing.com/news/insider-trading-news/daniel-ran-cfo-of-nanox-imaging-buys-3650-in-nnox-shares-93CH-4227813?utm_source=openai">investing.com</a>)</p>
<p>5) Growth Opportunities
- Hardware (ARC/ARC X)
  - US general‑use 510(k) and EU CE Mark broaden indications and commercial footprint; goal of &gt;100 systems in some stage of deployment worldwide by year‑end 2025 (management reiterated in Nov). (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanoxarc-imaging-system-receives-ce-mark-expanding-medical/?utm_source=openai">investors.nanox.vision</a>)
- AI distribution
  - 3DR Labs reseller partnership opens access to &gt;1,800 hospitals/imaging centers in the US; VasoHealthcare IT acquisition adds deployment capacity. (<a href="https://www.globenewswire.com/news-release/2025/11/18/3189949/0/en/Nanox-Announces-Strategic-Partnership-with-3DR-Labs-to-Expand-AI-Powered-Imaging-Solutions-Across-North-America.html?utm_source=openai">globenewswire.com</a>)
- Clinical validation and KOLs
  - Ongoing clinical work and new sites (e.g., Cedars‑Sinai; ECR 2025 data), which can underpin adoption and reimbursement discussions. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Geographic expansion
  - EU distributors/partners (EXRAY Czech Republic; Althea France), plus prior collaborations in Greece/Romania. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- 2026 outlook
  - Company guides to $35M revenue in 2026 as imaging and AI contributions scale. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)</p>
<p>6) Major Downside Risks
- Commercial execution: slower‑than‑expected installs/usage, and negative hardware/AI unit economics persisting. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Financing risk: continued cash burn (OCF $(30.4)M for 9M’25) could necessitate further equity raises/dilution. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Competitive response: entrenched OEMs with broad portfolios and service ecosystems (GEHC, SHL, PHG). (<a href="https://valueinvesting.io/GEHC/valuation/ev_ebitda-multiples?utm_source=openai">valueinvesting.io</a>)
- Regulatory/quality: need to maintain compliance and expand clearances; prior SEC settlement highlights need for strong disclosure controls. (<a href="https://www.sec.gov/enforcement-litigation/litigation-releases/lr-25876?utm_source=openai">sec.gov</a>)
- Macro/trade: med‑tech peers cite tariff headwinds and China demand softness; could affect pricing/supply chain. (<a href="https://www.investopedia.com/ge-healthcare-q1-fy2025-earnings-11724195?utm_source=openai">investopedia.com</a>)</p>
<p>7) Fair Value Estimate
- DCF (illustrative, high uncertainty)
  - Base assumptions: 2026 revenue $35M (company guidance); revenue grows to ~$250M by 2030; FCF margin ramps from negative in 2026 to ~12% by 2030; WACC 14%, terminal growth 3%.
  - Result: EV ≈ $150M; add net cash (post‑Nov raise): roughly $60–70M; equity value ≈ $210–220M, implying ~$3.00–$3.25/share on ~69M diluted shares. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Relative valuation (cross‑check)
  - NNOX EV/Sales TTM ~12–13x vs large‑cap OEMs ~2–3x and services peer RDNT EV/EBITDA ~21x. On 2026E sales of $35M, applying 4–6x EV/Sales (to reflect higher growth/risk) yields EV $140–$210M; equity ~$200–$280M ($2.50–$4.00/share) depending on net cash. (<a href="https://www.tipranks.com/stocks/nnox/financials/ratios?utm_source=openai">tipranks.com</a>)
- Scenario range (12‑month)
  - Bear: delays in installs/AI → 2026 sales &lt;$25M; multiple compresses (3x EV/Sales) → ~$1.75–$2.50.
  - Base: meet ~$35M; 5x EV/Sales → ~$3.00–$3.50.
  - Bull: faster adoption/large channel wins → 2026 $45–50M; 6–7x → ~$4.25–$5.25.</p>
<p>8) Wall Street Analyst Opinions
- Coverage and targets (recent)
  - Cantor Fitzgerald: Overweight; PTs cited between $6 and $9 in 2025, reiterated $7 after RSNA 2025. D. Boral Capital: Buy, PT ~$8–$10 (adjusted from $15 earlier in 2025). TipRanks shows mixed buy ratings with $6–$10.6 range in late 2025. (<a href="https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-rating-on-nanox-imaging-stock-93CH-4390834?utm_source=openai">investing.com</a>)
- Consensus snapshot (aggregators)
  - “Strong Buy” from two analysts; average PT ≈ $8.5 (StockAnalysis/TipRanks). Note: very small coverage universe. (<a href="https://stockanalysis.com/stocks/nnox/ratings/?utm_source=openai">stockanalysis.com</a>)</p>
<p>9) Major Investors &amp; Institutional Sentiment
- Institutional holders (select)
  - Vanguard, BlackRock, State Street, Morgan Stanley, Susquehanna (options) among holders; overall institutional ownership modest and fluid given micro‑cap status. Recent moves include Vanguard trimming in Q3’25; Susquehanna increasing exposure in Q2’25; Morgan Stanley cut earlier in 2025. (<a href="https://fintel.io/so/us/nnox/vanguard-group?utm_source=openai">fintel.io</a>)
- Insider ownership/activity
  - CFO share purchase in Sep 2025 (1,000 shares). (<a href="https://www.investing.com/news/insider-trading-news/daniel-ran-cfo-of-nanox-imaging-buys-3650-in-nnox-shares-93CH-4227813?utm_source=openai">investing.com</a>)</p>
<p>10) Recent Research Reports &amp; News (highlights, 2025)
- Q3’25 results and 2026 revenue guide to $35M (Nov 20). (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- 3DR Labs reseller partnership (&gt;1,800 US sites) (Nov 18). (<a href="https://www.globenewswire.com/news-release/2025/11/18/3189949/0/en/Nanox-Announces-Strategic-Partnership-with-3DR-Labs-to-Expand-AI-Powered-Imaging-Solutions-Across-North-America.html?utm_source=openai">globenewswire.com</a>)
- Agreement to acquire VasoHealthcare IT (Nov 19) to accelerate AI deployments. (<a href="https://www.globenewswire.com/news-release/2025/11/19/3190922/0/en/Nanox-Reaches-Agreement-with-Vaso-Corporation-to-Acquire-VasoHealthcare-IT-Accelerating-U-S-Rollout-of-AI-Solutions.html?utm_source=openai">globenewswire.com</a>)
- Registered direct offering ($15M) closed Nov 25. (<a href="https://www.sec.gov/Archives/edgar/data/0001795251/000121390025114902/ea0267192-6k_nanox.htm">sec.gov</a>)
- ARC X FDA 510(k) clearance (Apr 17); ARC general‑use clearance expansion (Dec 5, 2024); CE Mark for ARC (Feb 25). (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanox-receives-fda-clearance-general-use-new-imaging-system/?utm_source=openai">investors.nanox.vision</a>)
- New EU distributors (EXRAY, Althea France). (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Varex manufacturing agreement for tubes using Nanox digital source (2023; still relevant for supply chain). (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanox-announces-strategic-manufacturing-agreement-varex-imaging?utm_source=openai">investors.nanox.vision</a>)</p>
<p>11) Final Verdict / Investment Thesis
- Bull case
  - Regulatory de‑risking (FDA + CE), growing clinical validation, channel leverage (3DR Labs, EU partners), and integrated AI+telerad stack could drive an install base ramp and recurring software/service revenue. If 2026 guidance is met and AI deployments scale, multiple could expand from depressed levels. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Base case
  - Gradual install curve; teleradiology remains the core near‑term revenue with improving margins; AI and imaging contribute incrementally in 2026. Liquidity bolstered by Nov raise supports 12–24 months of execution runway at current burn. Valuation fair around low‑$3s pending proof of operating leverage. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Bear case
  - Slower adoption and persistent negative hardware/AI unit economics require further dilutive raises; competition and macro headwinds limit pricing and uptake. Prior disclosure issues underscore governance risk tolerance required. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
- Who is it suitable for?
  - High‑risk, small‑cap med‑tech investors comfortable with binary commercialization risk and dilution; not suitable for conservative income or value‑only mandates.
- Key 2026 catalysts to watch
  - Pace of US/EU ARC/ARC X installs and utilization; AI reseller traction (3DR Labs conversions), USARAD margin progression; any large system or health‑system wins; cash burn trend vs. guidance.</p>
<p>12) Key Resources
- Company IR/primary
  - Q3’25 press release (Nov 20, 2025) and webcast details; 2026 guide. (<a href="https://www.globenewswire.com/news-release/2025/11/20/3191845/0/en/Nanox-Announces-Third-Quarter-of-2025-Financial-Results-and-Provides-Business-Update.html">globenewswire.com</a>)
  - FDA/CE milestones: ARC general use (Dec 5, 2024); ARC X 510(k) (Apr 17, 2025); CE Mark (Feb 25, 2025). (<a href="https://investors.nanox.vision/news-releases/news-release-details/nanoxarc-imaging-system-receives-fda-clearance-general-use?utm_source=openai">investors.nanox.vision</a>)
  - 3DR Labs partnership; VasoHealthcare IT acquisition agreement. (<a href="https://www.globenewswire.com/news-release/2025/11/18/3189949/0/en/Nanox-Announces-Strategic-Partnership-with-3DR-Labs-to-Expand-AI-Powered-Imaging-Solutions-Across-North-America.html?utm_source=openai">globenewswire.com</a>)
  - 6‑K on $15M registered direct offering (Nov 25, 2025). (<a href="https://www.sec.gov/Archives/edgar/data/0001795251/000121390025114902/ea0267192-6k_nanox.htm">sec.gov</a>)
- Competitive/peer valuation context
  - GE HealthCare, Siemens Healthineers, Philips, RadNet valuation snapshots. (<a href="https://valueinvesting.io/GEHC/valuation/ev_ebitda-multiples?utm_source=openai">valueinvesting.io</a>)
- Governance/legal history
  - SEC settlement (Sept 29, 2023) and class action settlement notice (Dec 1, 2023). (<a href="https://www.sec.gov/enforcement-litigation/litigation-releases/lr-25876?utm_source=openai">sec.gov</a>)</p>
<p>Quick take
- NNOX has moved from regulatory risk to commercialization risk. Execution on installations and AI distribution in 2026 (against a relatively strong cash position for a micro‑cap) will likely determine whether the shares migrate toward the mid‑single digits (bullish case) or drift lower on dilution concerns (bear case). Near‑term, watch order flow, install cadence, and evidence that imaging and AI gross margins trend toward breakeven.</p>
<p>If you’d like, I can build a live valuation model you can tweak (installs, per‑site volumes, AI attach, opex) and set up KPI tracking for the next two quarters.</p>
    </body>
    </html>
    